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A program of routine varicella vaccination of children 12–18 months of age, begun in the United States in
1995, has been very successful in reducing the incidence of varicella. Varicella-zoster virus (VZV), in both
wild-type and live attenuated forms, is notable for its ability to produce latent infection of sensory neurons
from which it can later reactivate to cause herpes zoster (HZ). Therefore, the effects of vaccination on this
secondary VZV-related disease are important to consider; in practice, however, such studies are complicated
by the typically long delay between acquisition of the virus and its reactivation. Studies of immunocompromised
children have shown that vaccination is relatively protective against HZ in this highly vulnerable group. We
now present long-term follow-up data on a group of individuals who received varicella vaccine as healthy
young adults 10–26 years ago and who have been followed prospectively by means of active surveillance.
Among some 2000 person-years of follow-up, 2 cases of HZ have occurred, for a rate of 1.00 case/1000 person-
years. Overall, the incidence of HZ in this cohort, therefore, is similar to published data for the US population
in the prevaccine era.
In 1995, live attenuated varicella vaccine was licensed
for routine use with healthy varicella-susceptible chil-
dren and adults in the United States. More than 57
million doses of the vaccine have been distributed since.
The vaccine has been highly effective in preventing var-
icella, as judged by substantial reductions in varicella-
associated morbidity and mortality [1–4]. Although a
significant minority of vaccinees develop a modified
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form of varicella after exposure to varicella-zoster virus
(VZV), their illness usually is extremely mild [5–8].
The effects of widespread use of varicella vaccine on
the incidence of herpes zoster (HZ), the disease caused
by reactivation of VZV, are still being determined. Ini-
tially, there were fears that the incidence of HZ might
increase among vaccinees. The live attenuated varicella
vaccine retains the ability to establish latent infection
and to cause HZ that may be clinically indistinguishable
from wild-type disease [9]. In a passive postlicensure
surveillance study, typing of clinical specimens by poly-
merase chain reaction (PCR) analysis revealed that, of
56 suspected cases of HZ among vaccinees, 22 were
caused by vaccine-strain VZV and 10 by wild-type VZV
(the remaining specimens were inadequate for analysis,
negative, or untypeable) [9, 10]. Currently available
data do not enable an assessment of the rate at which
either type of HZ occurs among immunocompetent
individuals.
In unvaccinated populations, the main risk factors
for reactivation of VZV are advanced age and immu-
nosuppression. Results of several clinical studies of
VZV-naive immunocompromised children have sug-
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Table 1. Subject characteristics and clinical events, by follow-up period.
Follow-up
period,
yearsa
Subjects,
no.
Person-
years
Age at
vaccination,
mean (median),
years
Vaccine doses,
mean (median), no.
Seroconversion
rate, %b
HHE BV Person-years
after BV,
no. (%)Subjects, no. Rate/year Subjects, no. Rate/year
0–4.9 363 1242.1 28.2 (26.1) 1.8 (2) 82.1 87 0.070 29 0.023 30.8 (2.5)
5–9.9 129 459.3 28.4 (26.9) 1.9 (2) 89.9 16 0.035 10 0.022 29.6 (6.4)
10–14.9 64 213.6 28.1 (26.1) 1.8 (2) 89.1 5 0.023 0 0 14.2 (6.6)
15–19.9 28 68.5 27.3 (25.6) 1.8 (2) 82.1 0 0 0 0 1.7 (2.5)
20 6 12.2 24.2 (24.3) 1.5 (1.5) 100 0 0 0 0 0
Total 363 1995.7 28.0 (26.0) 2.0 (2) 82.4 108 0.054 39 0.02 76.3 (3.8)
NOTE. BV, breakthrough varicella; HHE, household exposure to varicella.
a Follow-up periods are grouped in accordance with years since vaccination.
b Seroconversion was defined as a fluorescent antibody to membrane antigen titer of 1:2 at 4–8 weeks after receipt of the final dose of vaccine. Rates are
for all study subjects that contributed person-years to the relevant follow-up period.
gested a protective effect against subsequent HZ (as well as
varicella) with varicella vaccination [11, 12].
In our laboratory, immunization of healthy young VZV-se-
ronegative adults against varicella began in 1979, in prelicensure
clinical trials. Many of these vaccinees were health care workers.
We have prospectively followed a cohort of 363 individuals for
up to 25 years, by means of active surveillance. We report the
incidence of HZ among these vaccinees, most of whom are
now middle-aged adults who normally would be considered to
be at increasing risk for HZ.
METHODS
The subjects participated in a variety of prelicensure clinical
trials of varicella vaccines between 1979 and 1995. The char-
acteristics of this group and details of their vaccination regimens
have been described in a previous report [13]. All studies re-
ceived institutional review board approval through Columbia
University (New York). In brief, subjects were healthy adults
with no clinical history of varicella and with serology results
negative for VZV (as determined by fluorescent antibody to
membrane antigen [FAMA] assay); many subjects were health
care workers. After informed consent was obtained, subjects
were immunized in accordance with a variety of trial protocols.
The majority of subjects received 2 doses (range, 1–3 doses)
of research-lot vaccines that differed in potency, from 1500 to
3000 pfu/dose (Merck vaccines) and up to 10,000 pfu/dose
(SmithKlineBeecham vaccines). Serologic responses were as-
sessed by FAMA assay between 4 and 8 weeks after vaccination
and at various intervals thereafter, in accordance with trial pro-
tocols. Samples of serum were obtained subsequently for testing
by FAMA assay at annual intervals, when possible. Subjects
were encouraged to contact study personnel and their own
physicians at the time of any exposure to or possible symptoms
of disease due to VZV, regardless of severity. When this oc-
curred, a clinical assessment, samples of serum for testing by
FAMA assay, and vesicular fluid for diagnostic studies (includ-
ing PCR analysis) were obtained. To elicit details of any pre-
viously unreported exposure to VZV and/or any episodes of
vesicular rash, subjects were contacted annually in the form of
a postal questionnaire or, if they failed to respond, by telephone
or letter.
In the current analysis, follow-up was timed from the date
of receipt of the first dose of varicella vaccine (i.e., first exposure
to vaccine-strain VZV) to the date of last follow-up contact.
Subjects with !1 year of follow-up were excluded from the
analysis. HZ was diagnosed by report and/or by virus isolation
and PCR analysis, as described elsewhere [9]. Person-years after
HZ were excluded from the analysis. All data were entered into
Microsoft Excel for analysis.
RESULTS
Study Sample and Follow-up Duration
A total of 363 healthy adults (median age, 26 years; range, 17.1–
56.7 years) were immunized against varicella and were followed
up for at least 12 months; the mean duration of follow-up was
5.5 years (median, 4 years; range, 1–26 years). At last follow-
up, subjects ranged in age from 21 to 62.7 years, with a mean
of 33.7 years and a median of 32.4 years. Table 1 shows the
distribution of person-years in our data set, by time since vac-
cination. The total number of evaluable person-years was 1996,
of which 754 and 294 person-years were 15 and 110 years,
respectively, after subject vaccination. Table 1 shows age at vac-
cination, number of vaccine doses received, rate of serocon-
version, and annualized rates of household exposure to varicella
and of breakthrough varicella, at various intervals, for study
subjects who remained in follow-up. Among study subjects who
dropped out within the first 5 years, the seroconversion rate
was 78%, whereas 90% of those in longer-term follow-up had
seroconversion immediately after vaccination. Rates of house-
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hold exposure to varicella and of breakthrough disease also
were somewhat higher during this early period of follow-up.
HZ
Only 2 cases of HZ occurred, for an overall rate of 2 cases/
1996 person-years (1.00 case/1000 person-years; 95% confi-
dence interval [CI], 0.12–3.62 cases/1000 person-years, by
Fisher’s exact test).
Case 1. Case 1 has been reported in detail elsewhere [14]
and was found to be due to wild-type VZV (on the basis of
typing of virus from vesicular fluid, by PCR analysis). The study
subject had shown initial seroconversion after 2 doses of var-
icella vaccine, but antibody titers waned by 20 months after
vaccination. Subsequently, she showed a secondary increase in
antibody titers after definite exposure to wild-type VZV. Despite
the lack of accompanying symptoms of breakthrough varicella,
the acquisition of wild-type VZV at that time was assumed,
which resulted in reactivation that caused classic thoracic der-
matomal HZ 6 months later. This subject was 33 years old at
the time of the development of HZ, which occurred 3 years
after she had received the varicella vaccine.
Case 2. Case 2 was reported as classic HZ affecting the left
shoulder, when the study subject was 53 years of age. She had
received 2 doses of varicella vaccine, administered to the left
deltoid, 11 years previously and did not have a history of vac-
cine-associated rash. As in case 1, this individual had shown a
secondary increase in VZV antibody titers after exposure to
varicella 4 years after vaccination (7 years prior to the devel-
opment of HZ). However, this exposure had been accompanied
by the development of 2 vesicles on the subject’s lower limb
that was thought to represent breakthrough varicella. Unfor-
tunately, no clinical samples were obtained from this subject
for PCR analysis for VZV. Thus, we do not know whether
vaccine-strain or wild-type VZV was responsible for her clin-
ically diagnosed episode of HZ.
DISCUSSION
HZ is not easy to study, whether at the epidemiological or
pathophysiological level. However, the advent of universal var-
icella vaccination in the United States has brought a new focus
to our efforts to understand the reactivation of VZV. The extent
to which vaccinated individuals harbor latent infection with
vaccine-strain VZV and the contribution that this makes to
protective immunity against varicella are unknown.
In the current study, we report the long-term incidence of
HZ among subjects who had received varicella vaccine as
healthy young adults in several prelicensure clinical trials. The
observed HZ incidence, at 1.00 case/1000 person-years, is
somewhat lower than previously observed rates of HZ among
unvaccinated populations, which ranged from 2.15 to 4.05
cases/1000 person-years [15–17]. This finding, therefore, is
consistent with the hypothesis that immunocompetent, vac-
cinated individuals are relatively protected against HZ, com-
pared with unvaccinated persons harboring wild-type VZV.
However, the CIs associated with the only 2 cases of HZ in
our study group are necessarily wide. We did not have a
control group in our study, and published data do not inform
on the incidence of HZ among the relevant control popula-
tion, namely, individuals who developed natural varicella as
adults. Comprehensive cross-sectional studies have concen-
trated on age at the time of development of HZ, rather than
the time since varicella, and give rates that increase steeply
with age, particularly after the sixth decade [15, 16].
It is argued that the relationship between advancing years
and the risk of HZ reflects an age-related decline in cell-me-
diated immunity against VZV. However, it seems likely that
this relationship would be offset at least partially by later ac-
quisition of primary VZV infection. Hence, the rate of HZ
among individuals acquiring wild-type VZV in adulthood
would be expected to lie somewhere between that of their age-
matched peers (most of whom had experienced varicella in
childhood) and that of younger people. Although rates of HZ
are lowest among children, Donohue et al. [15] estimated a
rate of 1.33 cases/1000 person-years among susceptible indi-
viduals in the age group !15 years. In the same study, rates of
HZ increased progressively with age, from 1.92 cases/1000 per-
son-years (age group, 25–34 years) to 3.13 cases/1000 person-
years (age group, 45–54 years). The extremes for these values
were similar to the 95% CIs of the incidence rates that we
found in our vaccinated cohort. Thus, we can surmise that, as
a group, our vaccinees have not obtained protection from var-
icella at the expense of an excess risk of HZ, when compared
with their age-matched peers. However, the degree to which
they may be protected against HZ, when compared with adults
who have had wild-type VZV infection, cannot be estimated
because of the lack of control subjects in this study.
Some other limitations of our study should be emphasized.
Follow-up data were partial, although the comparison pre-
sented in table 1 suggests that those subjects with longer follow-
up are likely to be representative of the original population.
Our data are heavily skewed toward the early years after vac-
cination (table 1) and, therefore, are less informative with re-
spect to the later risk of HZ. In addition, our study subjects
may have experienced higher than usual rates of occupational
exposure to VZV, which may be associated with protection
against HZ in adults who had varicella [18]. This same occu-
pational exposure of vaccinated adults may be associated with
an increase in the incidence of breakthrough varicella and per-
haps, subsequently, of HZ. With these caveats in mind, we
nonetheless are heartened by the relative rarity of HZ in this
aging population of vaccinees.
It has been shown previously that the risk of HZ in children
Risk of HZ in Adults • JID 2008:197 (Suppl 2) • S199
with leukemia is strongly linked to prior VZV-related rash,
whether caused by wild-type or vaccine-strain VZV [12]. This
observation is consistent with the hypothesis that latent VZV
infection follows the infection of sensory neurons that innervate
infected skin. Such a model suggests that HZ caused by vaccine-
strain VZV would be associated with a history of vaccine-as-
sociated rash, whereas HZ caused by wild-type VZV would be
associated with prior breakthrough varicella. The current data
do not enable us to address this issue. In future larger studies,
the influence of these relatively common complications on the
risk of HZ among vaccinees will be important to examine. In
our cohort, which experienced only a moderate rate of break-
through varicella (2%/person/year), 1 case of HZ occurred after
clinically evident breakthrough varicella, whereas the other case
appeared to have occurred after subclinical breakthrough var-
icella. We therefore must consider the possibility that there may
be an excess risk of HZ among the minority of individuals who
acquire wild-type VZV infection despite vaccination. Further-
more, we must recognize that this risk may be conferred even
if the breakthrough varicella is subclinical, as in case 1.
To document the changing epidemiology of HZ in the era
of varicella vaccination, large prospective studies currently are
in progress in sentinel areas of the United States. Interpretation
of their results will be complicated by the relative paucity of
historical data; furthermore, the data that are available suggest
that the incidence of HZ was increasing in all age groups before
the introduction of the varicella vaccination program [15].
Careful analysis will be required in order to distinguish between
the direct and indirect (herd) effects of mass vaccination, be-
cause of the potential impact of reduced virus circulation on
the longevity of immunity against HZ [18].
The Shingles Prevention Study (Veterans Affairs San Diego
Healthcare System) recently reported impressive trial data dem-
onstrating the efficacy of a high-potency varicella vaccine
among older individuals [19]. Such a vaccine shows the po-
tential for a significant reduction in the incidence of HZ. In
the meantime, our current data add to the existing body of
evidence suggesting that individuals vaccinated against varicella
are not at heightened risk of subsequently developing HZ.
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Note added in proof. Since this article was accepted for publication, additional person-years of follow-up have accrued,
producing a revised incidence of herpes zoster of 0.91 cases/1000 person-years (95% confidence interval, 15.3–300.6 cases/1000
person-years).
